Mineralocorticoid Receptor Antagonists
"Mineralocorticoid Receptor Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs that bind to and block the activation of MINERALOCORTICOID RECEPTORS by MINERALOCORTICOIDS such as ALDOSTERONE.
| Descriptor ID |
D000451
|
| MeSH Number(s) |
D06.347.700 D27.505.696.399.450.600 D27.505.696.560.500.726.249
|
| Concept/Terms |
Mineralocorticoid Receptor Antagonists- Mineralocorticoid Receptor Antagonists
- Antagonists, Mineralocorticoid Receptor
- Receptor Antagonists, Mineralocorticoid
- Mineralocorticoid Antagonists
- Antagonists, Mineralocorticoid
- Aldosterone Receptor Antagonists
- Antagonists, Aldosterone Receptor
- Receptor Antagonists, Aldosterone
|
Below are MeSH descriptors whose meaning is more general than "Mineralocorticoid Receptor Antagonists".
Below are MeSH descriptors whose meaning is more specific than "Mineralocorticoid Receptor Antagonists".
This graph shows the total number of publications written about "Mineralocorticoid Receptor Antagonists" by people in this website by year, and whether "Mineralocorticoid Receptor Antagonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 1 | 0 | 1 |
| 2002 | 1 | 0 | 1 |
| 2003 | 1 | 0 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 2 | 0 | 2 |
| 2009 | 1 | 2 | 3 |
| 2011 | 1 | 0 | 1 |
| 2021 | 0 | 1 | 1 |
| 2022 | 0 | 2 | 2 |
| 2024 | 0 | 1 | 1 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Mineralocorticoid Receptor Antagonists" by people in Profiles.
-
Mitigating heart failure risk in patients with diabetes and chronic kidney disease. Curr Opin Cardiol. 2025 May 01; 40(3):178-183.
-
National Trends in Hospital Performance in Guideline-Recommended Pharmacologic Treatment for Heart Failure at Discharge. JACC Heart Fail. 2024 Jun; 12(6):1059-1070.
-
Resistant hypertension: cardiorenal protection with mineralocorticoid receptor blockade. Eur Heart J. 2024 Jan 07; 45(2):136-138.
-
Estimated lifetime benefit of novel pharmacological therapies in patients with type 2 diabetes and chronic kidney disease: A joint analysis of randomized controlled clinical trials. Diabetes Obes Metab. 2023 11; 25(11):3327-3336.
-
Slowing the Progression of Diabetic Kidney Disease. Cells. 2023 07 31; 12(15).
-
Outcomes with Finerenone in Participants with Stage 4 CKD and Type 2 Diabetes: A FIDELITY Subgroup Analysis. Clin J Am Soc Nephrol. 2023 05 01; 18(5):602-612.
-
Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis. Eur Heart J Cardiovasc Pharmacother. 2023 02 02; 9(2):183-191.
-
The changing trajectory of diabetic kidney disease. Curr Opin Nephrol Hypertens. 2023 01 01; 32(1):98-102.
-
Blood Pressure and Cardiorenal Outcomes With Finerenone in Chronic Kidney Disease in Type 2 Diabetes. Hypertension. 2022 12; 79(12):2685-2695.
-
Aldosterone excess and cardiorenal risk: more common than appreciated. Eur Heart J. 2022 10 11; 43(38):3792-3793.